Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.

IF 2.3 4区 医学 Q3 ALLERGY
Joseph Najem, Alexandre Ton That, Connor Prosty, Ann E Clarke, Judy Morris, Jocelyn Gravel, Rodrick Lim, Edmond S Chan, Ran D Goldman, Andrew O Apos Keefe, Jennifer Gerdts, Derek K Chu, Julia E Upton, Elana Hochstadter, Jocelyn Moisan, Adam Bretholz, Christine McCusker, Xun Zhang, Jennifer L P Protudjer, Elissa Abrams, Elinor Simons, Andrew Dixon, Moshe Ben-Shoshan
{"title":"Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.","authors":"Joseph Najem, Alexandre Ton That, Connor Prosty, Ann E Clarke, Judy Morris, Jocelyn Gravel, Rodrick Lim, Edmond S Chan, Ran D Goldman, Andrew O Apos Keefe, Jennifer Gerdts, Derek K Chu, Julia E Upton, Elana Hochstadter, Jocelyn Moisan, Adam Bretholz, Christine McCusker, Xun Zhang, Jennifer L P Protudjer, Elissa Abrams, Elinor Simons, Andrew Dixon, Moshe Ben-Shoshan","doi":"10.1159/000552127","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The 2020 Protection of Students with Life-Threatening Allergies Act, obligates schools across Alberta, Canada to hold a common use stock of at least one epinephrine autoinjector (EAI) and to maintain a protocol for the prevention and management of anaphylaxis. Herein, we assessed the effectiveness of this policy by comparing pre-hospital EAI use before and after implementation of the act.</p><p><strong>Methods: </strong>The Cross-Canada Anaphylaxis Registry (C-CARE) enrolls patients presenting to a participating emergency department with anaphylaxis defined as the involvement of ≥2 systems and/or hypotension. Specific to this project, we extracted data on pediatric patients recruited from the Stollery Children's Hospital in Edmonton, Alberta from 2016 to 2024. Data were collected on demographics, comorbidities, symptomatology, pre- and intra-hospital management, and outcome of anaphylaxis by standardized chart review. Multivariable logistic regression was used to assess pre-hospital EAI use for cases occurring at school before versus after the enactment of the Act on January 1, 2020. Evaluating pre-hospital EAI use in Quebec and Ontario and antihistamine use pre versus post act in Alberta were used as negative controls.</p><p><strong>Result: </strong>Of the 59 cases of in-school anaphylaxis identified over the study period, 52.5% occurred post-act. The median age was 13.0 years (IQR = 9.5-15.8) and 40.7% were male. EAI use in schools was greater post-act versus pre-act (64.5% versus 35.7%, aOR = 3.82, 95% confidence interval [CI] = 1.24-11.7). There was no difference in pre-hospital EAI use pre versus post 2020 in Quebec and Ontario, that did not use the act (aOR = 0.72, 95% CI = 0.31-1.70). There was no difference in pre-hospital antihistamine use pre versus post act (aOR = 0.31, 95% CI = 0.07-1.41).</p><p><strong>Conclusion: </strong>Implementation of the provincial policy was associated with an increase in pre-hospital EAI use in cases of pediatric anaphylaxis occurring at school. These preliminary results support the effectiveness of policy interventions for anaphylaxis management.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3000,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13446875/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000552127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The 2020 Protection of Students with Life-Threatening Allergies Act, obligates schools across Alberta, Canada to hold a common use stock of at least one epinephrine autoinjector (EAI) and to maintain a protocol for the prevention and management of anaphylaxis. Herein, we assessed the effectiveness of this policy by comparing pre-hospital EAI use before and after implementation of the act.

Methods: The Cross-Canada Anaphylaxis Registry (C-CARE) enrolls patients presenting to a participating emergency department with anaphylaxis defined as the involvement of ≥2 systems and/or hypotension. Specific to this project, we extracted data on pediatric patients recruited from the Stollery Children's Hospital in Edmonton, Alberta from 2016 to 2024. Data were collected on demographics, comorbidities, symptomatology, pre- and intra-hospital management, and outcome of anaphylaxis by standardized chart review. Multivariable logistic regression was used to assess pre-hospital EAI use for cases occurring at school before versus after the enactment of the Act on January 1, 2020. Evaluating pre-hospital EAI use in Quebec and Ontario and antihistamine use pre versus post act in Alberta were used as negative controls.

Result: Of the 59 cases of in-school anaphylaxis identified over the study period, 52.5% occurred post-act. The median age was 13.0 years (IQR = 9.5-15.8) and 40.7% were male. EAI use in schools was greater post-act versus pre-act (64.5% versus 35.7%, aOR = 3.82, 95% confidence interval [CI] = 1.24-11.7). There was no difference in pre-hospital EAI use pre versus post 2020 in Quebec and Ontario, that did not use the act (aOR = 0.72, 95% CI = 0.31-1.70). There was no difference in pre-hospital antihistamine use pre versus post act (aOR = 0.31, 95% CI = 0.07-1.41).

Conclusion: Implementation of the provincial policy was associated with an increase in pre-hospital EAI use in cases of pediatric anaphylaxis occurring at school. These preliminary results support the effectiveness of policy interventions for anaphylaxis management.

加拿大阿尔伯塔省一项改善学校过敏反应中肾上腺素使用的省级法律的有效性:一项前后研究。
《2020年保护危及生命的过敏学生法案》要求加拿大艾伯塔省的学校持有至少一种肾上腺素自动注射器(EAI)的通用库存,并保持预防和管理过敏反应的协议。在此,我们通过比较该法案实施前后院前EAI的使用情况来评估该政策的有效性。方法跨加拿大过敏反应登记中心(C-CARE)纳入就诊于急诊科且过敏反应定义为≥2个系统和/或低血压的患者。具体到这个项目,我们提取了2016-2024年从艾伯塔省埃德蒙顿的斯托勒里儿童医院招募的儿科患者的数据。通过标准化的图表回顾收集了人口统计学、合并症、症状学、院前和院内管理以及过敏反应结果的数据。采用多变量logistic回归评估院前EAI在该法案于2020年1月1日颁布之前与之后在学校发生的病例的使用情况。评估魁北克省和安大略省院前EAI使用情况以及阿尔伯塔省院前和院后抗组胺使用情况作为阴性对照。结果在研究期间发现的59例学校过敏反应中,52.5%发生在法案后。中位年龄13.0岁(IQR=9.5 ~ 15.8),男性占40.7%。学校中EAI的使用在行动后高于行动前(64.5%对35.7%,aOR=3.82, 95%CI=1.24-11.7)。魁北克省和安大略省院前EAI的使用与2020年之后没有差异(aOR=0.72, 95%CI=0.31-1.70)。院前用药前后抗组胺药使用差异无统计学意义(aOR=0.31, 95%CI=0.07 ~ 1.41)。结论省级政策的实施与学校发生的儿童过敏反应的院前EAI使用增加有关。这些初步结果支持了过敏反应管理政策干预的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.60%
发文量
105
审稿时长
2 months
期刊介绍: ''International Archives of Allergy and Immunology'' provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书